期刊文献+

间质胶原酶在实验性肺高压肺血管重建中表达的动态改变 被引量:4

Gene expression of interstitial collagenase in pulmonary vascular remodeling of rats with pulmonary hypertension
下载PDF
导出
摘要 目的 探讨间质胶原酶基因表达在肺动脉高压肺血管重建中的作用。方法 利用野百合碱(monocrotaline ,MCT)诱导的大鼠肺高压动物模型 ,经导管介入测定大鼠肺动脉平均压力 ,逆转录定量聚合酶链反应 (RT PCR)检测不同时间点大鼠肺组织间质胶原酶mRNA相对表达水平。结果 实验第三周肺动脉平均压力已明显升高 ,以第四周为最高 ,而大鼠肺组织间质胶原酶mRNA表达水平以实验第二周最为明显 ,第三、四周表达水平下调 ,但仍高于对照组。结论 MMP 1基因表达异常参与了肺高压肺血管重建过程 ,其早期基因过度表达有助于细胞外基质屏障的降解 ,对肺血管重建可能起了触发作用。 Objective To explore the etiology of pulmonary hypertention with relation to the expression of intersitial collagenase in pulmonary tissue. Methods The pulmonary hypertension animal models were induced by the monocrotaline (MCT); the mean pulmonary arterial pressure was measured by catheterization; and the pulmonary intersitial collagenase mRNA expression was studied by RT PCR. Results The mean pulmonary arterial pressure was increased significantly in the 3rd week after the induction of moncrotaline and reached the peak in the 4 th weak; while the pulmonary interstitial collagenase mRNA expression was increased significantly in the second week and then decreased greatly in the 3rd and 4th but still higher than that in the 1st weak. Conclusion Abnormal interstitial collagenaes expression might take part in the remodeling pulmonary hypertension; early interstitial collagenase expression might facilitate the degradation of extracellular matrix barrier, thus triggering the pulmonary vascular remodeling process.
出处 《上海医学》 CAS CSCD 北大核心 2001年第11期667-670,共4页 Shanghai Medical Journal
关键词 间质胶原酶 基因表达 肺动脉高压 肺血管重建 pulmonasry hypertention interstitial collagenase gene expression
  • 相关文献

参考文献3

  • 1Tozzi C A,Am J Respir Cell Mol Biol,1998年,18卷,497页
  • 2Shlopov B V,Arthritis Rheum,1997年,40卷,2065页
  • 3Zhu L,J Clin Invest,1994年,94卷,1163页

同被引文献26

  • 1夏伟,赵翠芬,李福海,时庆,杨杰.MMP-1、MMP-3对高动力血流状态肺血管重建的影响[J].山东大学学报(医学版),2004,42(6):694-697. 被引量:7
  • 2吴永平,车东媛,刘绍春.肺动脉高压时腺泡内肺动脉壁胶原相对含量的改变[J].徐州医学院学报,1994,14(4):283-285. 被引量:2
  • 3陶为科,叶世铎,孙宗全,钱士玲,王慧君,胡宗义.先心病合并肺动脉高压病理学与血液动力学对比研究[J].中华胸心血管外科杂志,1994,10(4):299-301. 被引量:3
  • 4Rabinovitch M, Bothwell T, Hayakawa N, et al. Pulmonary arterial abnormalities in patients with congenital heart defects and pulmonary hypertension[J]. Lab Invest 1986,55 (6) :632-653.
  • 5Kolpakov V, Rekhter MD, Gordon D, et al. Effect of mechanical forces on growth and matrix protein synthesis in the in vitro pulmonary artery[J]. Cite Res,1995,77(4) :823-831.
  • 6Kenagy RD, Vergel S, Mattsson E, et al. The role of plasminogen, plasminogen ativators, and matrix metalloproteinases in primate arterial smooth muscle cell migration [ J ]. Am Heart Assoc, 1996, 16(11) : 1373-1382.
  • 7Niedzwiecki L,Teahan J, Harrison R K, et al. Substrate-specificity of the human matrix metalloproteinase stromelysin and the development of continuous fluorometric assays [ J ]. Biochemistry, 1992,31 (50) : 12618-12623.
  • 8Adatia I, Barrow SE, Stratton PD, et al. Vascular endothelial re- sponses, prostanoids ,and flow: thromboxane A sub-2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease[ J ]. Circulation, 1993,88 (5) :2117-2122.
  • 9Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension [ J ]. Circ Res ,2004,94 ( 8 ) : 1101-1108.
  • 10Carmosino MJ, Friesen RH, Doran A, et al. Perioperative complication in children with pulmonary hypertention Undergoing non- cardiac surgery or cardiac catheterization [ J ]. Anesth Analg, 2007,104(3 ) :521-527.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部